-
公开(公告)号：US08791091B2
公开(公告)日：2014-07-29
申请号：US13688584
申请日：2012-11-29
Applicant: Bristol-Myers Squibb Company
Inventor： Huji Turdi , Jon J. Hangeland , R. Michael Lawrence , Saleem Ahmad , Wei Meng , Robert Paul Brigance , Pratik Devasthale , Guohua Zhao
IPC: A61K31/675 , A61K31/4418 , A61K45/06 , A61K31/438 , A61K31/4439 , A61K31/5377 , C07D401/04 , C07D413/04 , C07D413/14 , C07F9/59 , C07D401/14 , C07D211/90 , C07D221/20
CPC classification number: A61K31/438 , A61K31/4418 , A61K31/4439 , A61K31/5377 , A61K31/675 , A61K45/06 , C07D211/86 , C07D211/90 , C07D221/20 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/14 , C07D407/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/14 , C07F9/4006 , C07F9/5352 , C07F9/59
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
Abstract translation: 本发明提供式（I）化合物或其立体异构体或其药学上可接受的盐，其中所有变量如本文所定义。 这些化合物是可用作药物的单酰基甘油酰基转移酶2型（MGAT2）抑制剂。
-
公开(公告)号：US12269819B2
公开(公告)日：2025-04-08
申请号：US17601942
申请日：2020-04-08
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Chunjian Liu , Jianxin Feng , Pratik Devasthale , Natesan Murugesan , Bruce A. Ellsworth , Alicia Regueiro-Ren , Susheel Jethanand Nara , Prasada Rao Jalagam , Manoranjan Panda
IPC: C07H17/02 , C07D405/04 , C07D405/14 , C07D409/14 , C07D417/14
Abstract: The present disclosure relates to compounds of Formula (I) or (II), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
-
公开(公告)号：US20210161869A1
公开(公告)日：2021-06-03
申请号：US17177327
申请日：2021-02-17
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Huji Turdi , Jon J. Hangeland , R. Michael Lawrence , Saleem Ahmad , Wei Meng , Robert Paul Brigance , Pratik Devasthale , Guohua Zhao
IPC: A61K31/438 , C07D405/14 , C07D221/20 , C07D401/12 , A61K31/4418 , C07D211/90 , C07D417/04 , C07D407/14 , A61K31/675 , C07D401/04 , C07D417/14 , C07D413/12 , A61K45/06 , C07D211/86 , C07F9/40 , C07D413/14 , C07D413/04 , A61K31/4439 , C07F9/535 , C07D401/14 , A61K31/5377 , C07D401/10 , C07F9/59
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
-
公开(公告)号：US10966967B2
公开(公告)日：2021-04-06
申请号：US16879810
申请日：2020-05-21
Applicant: Bristol-Myers Squibb Company
Inventor： Huji Turdi , Jon J. Hangeland , R. Michael Lawrence , Saleem Ahmad , Wei Meng , Robert Paul Brigance , Pratik Devasthale , Guohua Zhao
IPC: A61K31/438 , A61K31/675 , C07D211/90 , A61K31/4418 , C07D401/04 , A61K31/4439 , C07D413/04 , C07D221/20 , C07D413/14 , A61K31/5377 , C07D401/14 , A61K45/06 , C07D401/10 , C07D401/12 , C07D407/14 , C07D413/12 , C07D417/04 , C07D417/14 , C07F9/59 , C07F9/40 , C07D211/86 , C07F9/535 , C07D405/14
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
-
公开(公告)号：US10851098B2
公开(公告)日：2020-12-01
申请号：US16347829
申请日：2017-11-07
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Pratik Devasthale , Wei Wang
IPC: C07D471/04 , C07D401/12 , C07D401/14 , C07D403/12 , A61P35/00
Abstract: The present invention provides compounds of Formula (I): (Formula (I)), or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are inhibitors to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αv-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
-
Patent Agency Ranking
公开(公告)号：US20190256513A1
公开(公告)日：2019-08-22
申请号：US16347829
申请日：2017-11-07
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Pratik Devasthale , Wei Wang
IPC: C07D471/04 , A61P35/00 , C07D401/12 , C07D403/12 , C07D401/14
Abstract: The present invention provides compounds of Formula (I): (Formula (I)), or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are inhibitors to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αv-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
-
17.发明申请ARYL DIHYDROPYRIDINONE AND PIPERIDINONE MGAT2 INHIBITORS 有权ARYL DIHYDROPRIDINONE和PIPERIDINONE MGAT2 INHIBITORS公开(公告)号：US20130143843A1
公开(公告)日：2013-06-06
申请号：US13688584
申请日：2012-11-29
Applicant: Bristol-Myers Squibb Company
Inventor： Huji Turdi , Jon J. Hangeland , R. Michael Lawrence , Dong Cheng , Saleem Ahmad , Wei Meng , Robert Paul Brigance , Pratik Devasthale
IPC: A61K31/675 , A61K31/4418 , C07D401/04 , A61K31/4439 , C07D413/04 , A61K45/06 , A61K31/438 , C07D413/14 , A61K31/5377 , C07F9/59 , C07D401/14 , C07D211/90 , C07D221/20
CPC classification number: A61K31/438 , A61K31/4418 , A61K31/4439 , A61K31/5377 , A61K31/675 , A61K45/06 , C07D211/86 , C07D211/90 , C07D221/20 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/14 , C07D407/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/14 , C07F9/4006 , C07F9/5352 , C07F9/59
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
Abstract translation: 本发明提供式（I）化合物或其立体异构体或其药学上可接受的盐，其中所有变量如本文所定义。 这些化合物是可用作药物的单酰基甘油酰基转移酶2型（MGAT2）抑制剂。
-
公开(公告)号：US11884661B2
公开(公告)日：2024-01-30
申请号：US17184179
申请日：2021-02-24
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Guohua Zhao , Pratik Devasthale , Xiang-Yang Ye , Kumaravel Selvakumar , Suresh Dhanusu , Palanikumar Balasubramanian , Leatte R. Guernon , Rita Civiello , Xiaojun Han , Michael Frederick Parker , Swanee E. Jacutin-Porte
IPC: C07D471/04 , C07D491/04 , C07D519/00 , A61P11/00 , A61P19/10 , A61P35/00 , A61P37/06
CPC classification number: C07D471/04 , A61P11/00 , A61P19/10 , A61P35/00 , A61P37/06 , C07D491/04 , C07D519/00
Abstract: The present invention provides compounds of Formula (I):
or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αV-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αv-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.-
公开(公告)号：US20210188847A1
公开(公告)日：2021-06-24
申请号：US17184179
申请日：2021-02-24
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Guohua Zhao , Pratik Devasthale , Xiang-Yang Ye , Kumaravel Selvakumar , Suresh Dhanusu , Palanikumar Balasubramanian , Leatte R. Guernon , Rita Civiello , Xiaojun Han , Michael Frederick Parker , Swanee E. Jacutin-Porte
IPC: C07D471/04 , A61P37/06 , A61P11/00 , A61P19/10 , A61P35/00 , C07D519/00 , C07D491/04
Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αV-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αv-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
-
20.发明授权公开(公告)号：US11014922B2
公开(公告)日：2021-05-25
申请号：US16347849
申请日：2017-11-07
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Pratik Devasthale , Fang Moore , Guohua Zhao , Susan Nicole Pieniazek , Kumaravel Selvakumar , Suresh Dhanusu , Manoranjan Panda , Lawrence R. Marcin
IPC: C07D471/04 , A61K31/4375 , A61P1/16 , A61P13/12 , A61P11/00 , A61P35/00
Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of av-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
-
-
-
-
-
-
-
-
-
Search Results
31
records
(took 0.026 seconds)
